Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Нестероидные противовоспалительные препараты: фокус на безопасность
Нестероидные противовоспалительные препараты: фокус на безопасность
И.Г.Пахомова, Е.Ю.Павлова. Нестероидные противовоспалительные препараты: фокус на безопасность. Consilium Medicum. Неврология (Прил.). 2014; 1: 8-13.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. McNamara D. Gastrooesophageal reflux disease and ulcer disease in Europe: NSAID-related gastroduodenal pathology. The Burden of Gastrointestinal Diseases in Europe. 2004: 31–6.
2. Lee T, Bartle B, Weiss K. Impact of NSAIDS on mortality and the effect of preexisting coronary artery disease in US veterans. Am J Med 2007; 120 (1): 98–104.
3. Kean WF, Buchanan WW. The use of NSAIDs in rheumatic disorders 2005: a global perspective. Inflammopharmacology 2005; 13 (4): 343–70.
4. Merle V, Thiefin G, Czernichow P. Epidemiology of gastroduodenal complications associated with nonsteroidal anti-inflammatory drug use Gastroenterol. Clin Biol 2004; 28: 27–36.
5. Laporte J, Ibanez L, Vidal X et al. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Safety 2004; 27: 411–20.
6. Hawkey CJ, Lain L et al. Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials. Aliment Pharmacol Ther 2001; 15 (10): 1593–601.
7. Каратеев А.Е., Яхно Н.Н., Лазебник Л.Б. и др. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. М., 2009.
8. Ponsoda X, Pareja E, Gomez-Lechon MJ et al. Drug biotransformation by human hepatocytes. In vitro/in vivo metabolism by cells from the same donor. J Hepatol 2001; 34: 19–24.
9. Walker AM. Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal antiinflammatory drugs. Arthritis Rheum 1997; 40: 201–8.
10. Bhala N, Plevris JN. Portal hypertensive enteropathy; an usual cause of gastrointestinal bleeding in cirrhosis: or is it? JR Coll Physicians 2006; 36: 208–10.
11. Boelsterli U. Nimesulide and hepatic adverse affects: roles of reactive metabolites and host factors. Int J Clin Pract 2002; 128: 30–6.
12. Warner JJ, Weideman RA, Kelly KC et al. The risk of acute myocardial infarction with etodolac is not increased compared to naproxen: a historical cohort analysis of a generic COX 2 selective inhibitor J Cardiovasc Pharmacol Ther 2008; 13 (4): 252–60.
13. Press release «EMEA recommends strengthening warnings and contraindications for etoricoxib-containing medicines used in the treatment of rheumatoid arthritis and ankylosing spondylitis», EMEA/CHMP/333636/2008, http://www.emea.europea.eu
14. Lanas A, Garcia-Rodriguez LA, Polo-Tomas M et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol 2009; 104 (7): 1633-41.
15. Laharie D, Droz-Perroteau C, Bеnichou J et al. Hospitalizations for gastrointestinal and cardiovascular events in the CADEUS cohort of traditional or Coxib NSAID users. Br J Clin Pharmacol 2010; 69 (3): 295–302.
16. Castellsague J, Pisa F, Rosolen V et al. Risk of upper gastrointestinal complications in a cohort of users of nimesulide and other nonsteroidal anti-inflammatory drugs in Friuli Venezia Giulia, Italy. Pharmacoepidemiol Drug Saf 2013; 22 (4): 365–75. doi: 10.1002/pds.3385. Epub 2012 Dec 11.
17. Каратеев А.Е. Новые данные по безопасности НПВП: осложнений меньше, чем мы думали раньше. Cons. Med. Неврология/ревматология (Прил.). 2010; 2: 48–55.
18. Rainsford K. Nimesulide – a multifactorial approach to inflammation and pain: scientific and. clinical consensus. Curr Med Res Opin 2006; 22 (6): 1161–70.
19. Conforti A, Leone R, Moretti U et al. Adverse drug reactions related to the use of NSAIDs with a focus on nimesulide: results of spontaneous reporting from a Northern Italian area. Drug Saf 2001; 24: 1081–90.
20. Laporte J, Ibanez L, Vidal X et al. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Safety 2004; 27: 411–20.
21. Каратеев А.Е. Российский опыт применения нимесулида: обзор клинических испытаний. Cons. Med. 2011; 13 (9): 89–95.
22. Larson A, Polson J, Fontana R et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005; 42 (6): 1364–72.
23. Traversa G, Bianchi C, Da Cas R et al. Cohort study of hepatotoxity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ 2003; 327: 18–22.
24. Irish Board Suspends Marketing of Drugs Containing Nimesulide. Электронный ресурс: http://www.imb.ie
25. European Medicines Evaluation Agency, Committee for Proprietary Medicinal Products. Nimesulide containing medicinal products. EMEA/432604/2007 http://www.emea.europea.eu
26. Press release. 23/06/2011 European Medicines Agency concludes review of systemic nimesuli-de-containing medicines. Электронный ресурс: http://www.ema.europa.eu/ema
27. Каратеев А.Е., Алексеева Л.И., Братыгина Е.А., Аширова Т.Б. Оценка частоты развития побочных эффектов при длительном применении нимесулида в реальной клинической практике. РМЖ. 2009; 17 (21): 1466–72.
2. Lee T, Bartle B, Weiss K. Impact of NSAIDS on mortality and the effect of preexisting coronary artery disease in US veterans. Am J Med 2007; 120 (1): 98–104.
3. Kean WF, Buchanan WW. The use of NSAIDs in rheumatic disorders 2005: a global perspective. Inflammopharmacology 2005; 13 (4): 343–70.
4. Merle V, Thiefin G, Czernichow P. Epidemiology of gastroduodenal complications associated with nonsteroidal anti-inflammatory drug use Gastroenterol. Clin Biol 2004; 28: 27–36.
5. Laporte J, Ibanez L, Vidal X et al. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Safety 2004; 27: 411–20.
6. Hawkey CJ, Lain L et al. Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials. Aliment Pharmacol Ther 2001; 15 (10): 1593–601.
7. Каратеев А.Е., Яхно Н.Н., Лазебник Л.Б. и др. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. М., 2009.
8. Ponsoda X, Pareja E, Gomez-Lechon MJ et al. Drug biotransformation by human hepatocytes. In vitro/in vivo metabolism by cells from the same donor. J Hepatol 2001; 34: 19–24.
9. Walker AM. Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal antiinflammatory drugs. Arthritis Rheum 1997; 40: 201–8.
10. Bhala N, Plevris JN. Portal hypertensive enteropathy; an usual cause of gastrointestinal bleeding in cirrhosis: or is it? JR Coll Physicians 2006; 36: 208–10.
11. Boelsterli U. Nimesulide and hepatic adverse affects: roles of reactive metabolites and host factors. Int J Clin Pract 2002; 128: 30–6.
12. Warner JJ, Weideman RA, Kelly KC et al. The risk of acute myocardial infarction with etodolac is not increased compared to naproxen: a historical cohort analysis of a generic COX 2 selective inhibitor J Cardiovasc Pharmacol Ther 2008; 13 (4): 252–60.
13. Press release «EMEA recommends strengthening warnings and contraindications for etoricoxib-containing medicines used in the treatment of rheumatoid arthritis and ankylosing spondylitis», EMEA/CHMP/333636/2008, http://www.emea.europea.eu
14. Lanas A, Garcia-Rodriguez LA, Polo-Tomas M et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol 2009; 104 (7): 1633-41.
15. Laharie D, Droz-Perroteau C, Bеnichou J et al. Hospitalizations for gastrointestinal and cardiovascular events in the CADEUS cohort of traditional or Coxib NSAID users. Br J Clin Pharmacol 2010; 69 (3): 295–302.
16. Castellsague J, Pisa F, Rosolen V et al. Risk of upper gastrointestinal complications in a cohort of users of nimesulide and other nonsteroidal anti-inflammatory drugs in Friuli Venezia Giulia, Italy. Pharmacoepidemiol Drug Saf 2013; 22 (4): 365–75. doi: 10.1002/pds.3385. Epub 2012 Dec 11.
17. Каратеев А.Е. Новые данные по безопасности НПВП: осложнений меньше, чем мы думали раньше. Cons. Med. Неврология/ревматология (Прил.). 2010; 2: 48–55.
18. Rainsford K. Nimesulide – a multifactorial approach to inflammation and pain: scientific and. clinical consensus. Curr Med Res Opin 2006; 22 (6): 1161–70.
19. Conforti A, Leone R, Moretti U et al. Adverse drug reactions related to the use of NSAIDs with a focus on nimesulide: results of spontaneous reporting from a Northern Italian area. Drug Saf 2001; 24: 1081–90.
20. Laporte J, Ibanez L, Vidal X et al. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Safety 2004; 27: 411–20.
21. Каратеев А.Е. Российский опыт применения нимесулида: обзор клинических испытаний. Cons. Med. 2011; 13 (9): 89–95.
22. Larson A, Polson J, Fontana R et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005; 42 (6): 1364–72.
23. Traversa G, Bianchi C, Da Cas R et al. Cohort study of hepatotoxity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ 2003; 327: 18–22.
24. Irish Board Suspends Marketing of Drugs Containing Nimesulide. Электронный ресурс: http://www.imb.ie
25. European Medicines Evaluation Agency, Committee for Proprietary Medicinal Products. Nimesulide containing medicinal products. EMEA/432604/2007 http://www.emea.europea.eu
26. Press release. 23/06/2011 European Medicines Agency concludes review of systemic nimesuli-de-containing medicines. Электронный ресурс: http://www.ema.europa.eu/ema
27. Каратеев А.Е., Алексеева Л.И., Братыгина Е.А., Аширова Т.Б. Оценка частоты развития побочных эффектов при длительном применении нимесулида в реальной клинической практике. РМЖ. 2009; 17 (21): 1466–72.
Авторы
И.Г.Пахомова, Е.Ю.Павлова
ГБОУ ВПО Северо-Западный государственный медицинский университет им. И.И.Мечникова Минздрава России, Санкт-Петербург
ГБОУ ВПО Северо-Западный государственный медицинский университет им. И.И.Мечникова Минздрава России, Санкт-Петербург
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.